Report : Middle East & Africa Infectious Disease Diagnostics Market Forecast to 2030 - Regional Analysis - By Product (Kits & Reagents, Instruments, and Software & Services), Technology (Biosensor-Based, Immunodiagnostics, Molecular-Based Diagnostic Techniques, Clinical Biology, and Others), Application Type (Laboratory Testing and Point-of-Care Testing), Testing Type (Human Testing and Veterinary Testing), and End User (Diagnostic Laboratories, Hospitals & Clinics, Research Institutes, Homecare Settings, and Others)
At 3.5% CAGR, the Middle East & Africa Infectious Disease Diagnostics Market is Speculated to be Worth US$ 1,576.80 Million by 2030, Says Business Market Insights
According to Business Market Insights' research, the Middle East & Africa infectious disease diagnostics market was valued at US$ 1,193.19 million in 2022 and is expected to reach US$ 1,576.80 million by 2030, registering a CAGR of 3.5% from 2022 to 2030. Increasing focus on R&D and funding in infectious disease diagnostics and rising incidence of infectious diseases are among the critical factors attributed to the Middle East & Africa infectious disease diagnostics market expansion.
Research and development (R&D) is an essential component of the business of pharmaceutical and biopharmaceutical companies. R&D enables market players to come up with new products for various therapeutic applications with significant medical and commercial potential. Moreover, leading market players invest in R&D to develop advanced technologies and generate more revenue. In response to the growing cases of infectious diseases and the shortage of laboratory capabilities and molecular testing reagents, some diagnostic testing manufacturers offer fast and easy-to-use devices to facilitate out-of-laboratory testing. The simple test kits detect proteins of pathogens from samples or human antibodies that are produced in response to infection in blood or serum. Thus, rising focus on R&D and funding in infectious disease diagnostics is expected to create lucrative opportunities for the growth of the Middle East & Africa infectious disease diagnostics market.
On the contrary, inadequate reimbursement scenario hampers the growth of Middle East & Africa infectious disease diagnostics market.
Based on product, the Middle East & Africa infectious disease diagnostics market is segmented into kits & reagents, instruments, and software & services. The kits & reagents segment held 68.5% share of the Middle East & Africa infectious disease diagnostics market in 2022, amassing US$ 817.37 million. It is projected to garner US$ 1,062.48 million by 2030 to expand at 3.3% CAGR during 2022-2030.
By technology, the Middle East & Africa infectious disease diagnostics market is segmented into biosensor-based, immunodiagnostics, molecular-based diagnostic techniques, clinical biology, and others. The molecular-based diagnostic techniques segment held 46.4% share of the Middle East & Africa infectious disease diagnostics market in 2022, amassing US$ 553.06 million. It is projected to garner US$ 764.94 million by 2030 to expand at 4.1% CAGR during 2022-2030. The immunodiagnostics segment is further subsegmented into enzyme-linked immunosorbent assay (ELISA), western blotting analysis, and immunofluorescence assay. The molecular-based diagnostic techniques segment is further subsegmented into polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), next-generation sequencing (NGS), DNA microarrays, and others.
By application type, the Middle East & Africa infectious disease diagnostics market is bifurcated into laboratory testing and point-of-care testing. The laboratory testing segment held 82.2% share of the Middle East & Africa infectious disease diagnostics market in 2022, amassing US$ 980.36 million. It is projected to garner US$ 1,266.51 million by 2030 to expand at 3.3% CAGR during 2022-2030.
By testing type, the Middle East & Africa infectious disease diagnostics market is bifurcated into human testing and veterinary testing. The human testing segment held 86.3% share of the Middle East & Africa infectious disease diagnostics market in 2022, amassing US$ 1,029.71 million. It is projected to garner US$ 1,322.89 million by 2030 to expand at 3.2% CAGR during 2022-2030. The human testing segment is further subsegmented into HIV, hepatitis, HAIs, HPV, tuberculosis, influenza, and others.
By end user, the Middle East & Africa infectious disease diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, research institutes, homecare settings, and others. The diagnostic laboratories segment held 43.0% share of the Middle East & Africa infectious disease diagnostics market in 2022, amassing US$ 513.56 million. It is projected to garner US$ 693.81 million by 2030 to expand at 3.8% CAGR during 2022-2030.
Based on country, the Middle East & Africa infectious disease diagnostics market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. The Rest of Middle East & Africa held 34.9% share of Middle East & Africa infectious disease diagnostics market in 2022, amassing US$ 416.54 million. It is projected to garner US$ 537.85 million by 2030 to expand at 3.2% CAGR during 2022-2030.
Key players operating in the Middle East & Africa infectious disease diagnostics market are Abbott Laboratories, Bruker Corp, Cardinal Health Inc, F. Hoffmann-La Roche Ltd, Trinity Biotech Plc, Danaher Corp, Bio-Rad Laboratories Inc, ACON Laboratories Inc, and DiaSorin SpA, among others.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com